CN121319180A - 靶向PD-L1和TGF-β的双功能分子 - Google Patents

靶向PD-L1和TGF-β的双功能分子

Info

Publication number
CN121319180A
CN121319180A CN202511294608.4A CN202511294608A CN121319180A CN 121319180 A CN121319180 A CN 121319180A CN 202511294608 A CN202511294608 A CN 202511294608A CN 121319180 A CN121319180 A CN 121319180A
Authority
CN
China
Prior art keywords
seq
cancer
antibody
cdr2
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511294608.4A
Other languages
English (en)
Chinese (zh)
Inventor
巩文词
钭一伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biotechnology Co ltd
Original Assignee
Lepu Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Biotechnology Co ltd filed Critical Lepu Biotechnology Co ltd
Publication of CN121319180A publication Critical patent/CN121319180A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202511294608.4A 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子 Pending CN121319180A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105286 2020-07-28
CN2020105286 2020-07-28
CNPCT/CN2021/098476 2021-06-04
CN2021098476 2021-06-04
CN202180061312.1A CN116348493B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
PCT/CN2021/108643 WO2022022503A1 (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting pd-l1 and tgf-beta

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180061312.1A Division CN116348493B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子

Publications (1)

Publication Number Publication Date
CN121319180A true CN121319180A (zh) 2026-01-13

Family

ID=80037607

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202511294608.4A Pending CN121319180A (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
CN202411428879.XA Active CN119462927B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
CN202180061312.1A Active CN116348493B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
CN202411428806.0A Active CN119409832B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411428879.XA Active CN119462927B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
CN202180061312.1A Active CN116348493B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子
CN202411428806.0A Active CN119409832B (zh) 2020-07-28 2021-07-27 靶向PD-L1和TGF-β的双功能分子

Country Status (9)

Country Link
US (1) US20230287125A1 (https=)
EP (1) EP4188950A4 (https=)
JP (3) JP2023540436A (https=)
KR (1) KR20230050356A (https=)
CN (4) CN121319180A (https=)
AU (1) AU2021317376A1 (https=)
IL (1) IL299966A (https=)
PH (1) PH12023550193A1 (https=)
WO (1) WO2022022503A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508210A (ja) * 2023-02-20 2026-03-10 中山康方生物医▲藥▼有限公司 ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108779180B (zh) * 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
EP3369745B1 (en) * 2016-08-04 2021-09-29 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 nanobody and use thereof
EP3551659A1 (en) * 2016-12-08 2019-10-16 Eli Lilly and Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
AU2018264455B2 (en) * 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019185029A1 (en) * 2018-03-29 2019-10-03 I-Mab Anti-pd-l1 antibodies and uses thereof
BR112021003093A2 (pt) * 2018-08-22 2021-05-11 Merck Patent Gmbh tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
US12559539B2 (en) * 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
US10851157B2 (en) * 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US11028174B1 (en) * 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
CN112940134B (zh) * 2021-05-11 2021-09-03 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白

Also Published As

Publication number Publication date
CN119462927B (zh) 2025-07-29
EP4188950A1 (en) 2023-06-07
PH12023550193A1 (en) 2024-06-24
WO2022022503A1 (en) 2022-02-03
JP2023540436A (ja) 2023-09-25
JP2025010203A (ja) 2025-01-20
IL299966A (en) 2023-03-01
KR20230050356A (ko) 2023-04-14
CN116348493B (zh) 2025-10-17
CN119409832B (zh) 2025-08-01
EP4188950A4 (en) 2025-01-22
US20230287125A1 (en) 2023-09-14
JP2026015500A (ja) 2026-01-29
CN116348493A (zh) 2023-06-27
JP7846734B2 (ja) 2026-04-15
CN119462927A (zh) 2025-02-18
CN119409832A (zh) 2025-02-11
AU2021317376A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US11634490B2 (en) Blocking antibodies against CD47 and methods of use thereof
CN102421482B (zh) 特异性针对可溶型ctla-4的抗体分子
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
WO2017084495A1 (zh) Pd-l1抗体、其抗原结合片段及其医药用途
US11497769B2 (en) Anti-CD19 antibodies
CN116745317B (zh) 抗tigit抗体及其用途
TWI821699B (zh) 抗b7h4抗體及其雙抗和應用
JP7419238B2 (ja) Ｐｄ１結合剤
US11028174B1 (en) Bifunctional molecules targeting PD-L1 and TGF-β
JP2023524102A (ja) Ａｂｃｂ５に特異的な抗体およびその使用
WO2022171100A1 (zh) Gpc3人源化抗体及其应用
CN110172099A (zh) 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
JP2026015500A (ja) Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
CN115368457A (zh) 抗tigit抗体及其用途
HK40088153A (zh) 靶向PD-L1和TGF-β的双功能分子
HK40070445A (en) Anti-b7h4 antibody, and bispecific antibody and use thereof
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40130450

Country of ref document: HK